國立虎尾科技大學 |

Resistance of targeted therapies excluding antibodies for lymphomas

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Resistance of targeted therapies excluding antibodies for lymphomas/ edited by Andres J. M. Ferreri.
其他作者:	Ferreri, Andres J. M.
出版者:	Cham :Springer International Publishing : : 2018.,
面頁冊數:	xiii, 138 p. :ill. (some col.), digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Lymphomas - Chemotherapy. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-75184-9
ISBN:	9783319751849

Resistance of targeted therapies excluding antibodies for lymphomas
Resistance of targeted therapies excluding antibodies for lymphomas[electronic resource] /edited by Andres J. M. Ferreri. - Cham :Springer International Publishing :2018. - xiii, 138 p. :ill. (some col.), digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.172196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..

Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents -- Chapter 2 BCL2 Inhibitors: insights into resistance -- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib -- Chapter 4 IMiD - immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms -- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents -- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents.

In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.

ISBN: 9783319751849

Standard No.: 10.1007/978-3-319-75184-9doiSubjects--Topical Terms:

1201644
Lymphomas
--Chemotherapy.

LC Class. No.: RC280.L9 / R475 2018

Dewey Class. No.: 616.99446061

Resistance of targeted therapies excluding antibodies for lymphomas
LDR:02320nam a2200325 a 4500 001 924549
003 DE-He213
005 20180830165534.0
006 m d
007 cr nn 008maaau
008 190625s2018 gw s 0 eng d
020 $a 9783319751849 $q (electronic bk.)
020 $a 9783319751832 $q (paper)
024 7 $a 10.1007/978-3-319-75184-9 $2 doi
035 $a 978-3-319-75184-9
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.L9 $b R475 2018
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99446061 $2 23
090 $a RC280.L9 $b R433 2018
245 0 0 $a Resistance of targeted therapies excluding antibodies for lymphomas $h [electronic resource] / $c edited by Andres J. M. Ferreri.
260 $a Cham : $c 2018. $b Springer International Publishing : $b Imprint: Springer,
300 $a xiii, 138 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.17
505 0 $a Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents -- Chapter 2 BCL2 Inhibitors: insights into resistance -- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib -- Chapter 4 IMiD - immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms -- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents -- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents.
520 $a In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.
650 0 $a Lymphomas $x Chemotherapy. $3 1201644
650 0 $a Drug targeting. $3 581035
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Molecular Medicine. $3 668353
700 1 $a Ferreri, Andres J. M. $3 1201643
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.4. $3 1063064
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-75184-9
950 $a Biomedical and Life Sciences (Springer-11642)